Head-to-Head: which drug tames mania best?
NCT ID NCT07665073
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two approved antipsychotic drugs, risperidone and cariprazine, in 50 adults with bipolar 1 disorder experiencing acute mania. Participants take one of the drugs for 6 weeks, and doctors measure how well symptoms improve using a standard mania rating scale. The goal is to see which drug works better and has fewer side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Risperidone and Cariprazine (antipsychotic drugs)
What this could lead to
If this trial shows one drug works better or has fewer side effects, it could help doctors choose the best treatment for manic episodes in bipolar disorder.
What could go wrong
This is a small, early-stage comparison with only 50 people. Results may not apply to everyone, and both drugs already have known side effects like drowsiness or weight gain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIPOLAR 1 DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••